A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...

Promising phase 3 trial results from French researchers indicate that the first-in-class oral TKI masitinib may provide a new treatment option for patients with primary progressive multiple sclerosis ...

PHILADELPHIA, Pennsylvania (WPVI) -- "Women represent a huge portion of the people with MS," said Linda McAleer. "So, we got together 20 years ago and put a program together that would invite us all ...

Over time, MS treatment patterns have changed as several new DMTs have been approved; this has increased treatment options for both patients and providers. Convenience of administration, insurance ...

In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are not ...

Professional societies of neurologists, including most prominently the American Academy of Neurology (AAN) and the European Academy of Neurology (EAN) periodically release recommendations to guide ...

Significantly higher levels of HRQoL were reported in patients who lived in cities, had lower MS severity and fatigue, had higher cognitive processing speed, and had achieved higher educational ...

Multiple sclerosis (MS) is a chronic, inflammatory autoimmune disease that affects the central nervous system (the brain and spinal cord). In MS, the immune system attacks the protective covering ...